Biotechnology

#Biotechnology #CAR-T #Flow Cytometry #Tumour #Webinar

Webinar: Imaging for target discovery for CAR T cell therapy

In this free webinar, Dr. Christoph Herbel presents a newly developed workflow which combines flow cytometry–based screenings with high-parameter imaging to identify and validate new tumour markers in an unbiased approach.   The event, Kill the tumour, spare the healthy tissue. Ultra high-content imaging enables target discovery for CAR T cell therapy, was hosted by DDW and supported by Miltenyi Biotec.  It… Read More

#News #Trending News

#Biotechnology #Clinical trials #Immunotherapy #Therapeutics #Tumours

Biotheus’ bifunctional therapeutic FDA-approved to enter Phase II studies 

Biotheus, a biotechnology company based in Zhuhai, China, with multiple clinical-stage assets under clinical development, has announced that its anti-PD-L1/TGF-β bifunctional therapeutic, named PM8001, has been approved by the United States Food and Drug Administration (FDA) for conducting clinical Phase II studies as part of an international multicentre clinical trial. … Read More

#News

#Antibodies #Biotechnology #Cancer research #Immunotherapy #Therapeutics

MImAbs acquires antibody discovery system

MImAbs has acquired the Berkeley Lights Beacon system via a TechAccess subscription to help its customers in the generation and validation of novel therapeutic antibodies against cancer and inflammatory diseases.  The acquisition  This marks the first Beacon platform to be used in France, which enables MImAbs to provide research institutions,… Read More

#News

#Biotechnology #Covid-19 #Drug discovery #Immunology / Virology & Vaccines

Covid-19 treatment cuts hospitalisation and death by 79% 

The Medicines and Healthcare products Regulatory Agency (MHRA), in the UK, has approved GSK and Vir Biotechnology’s Covid-19 drug Xevudy (sotrovimab), after it was found to be safe and effective at reducing the risk of hospitalisation and death in people with mild to moderate Covid-19 infection who are at an increased risk of developing severe… Read More

#Covid-19 #News #Trending News

#Biotechnology #Drug development #Immunology / Virology & Vaccines #Microbiome #R&D

Sanofi acquisition is move for acne vaccine candidate 

Sanofi will acquire Origimm Biotechnology in December 2021, an Austrian biotechnology company specialising in the discovery of virulent skin microbiome components and antigens from bacteria-causing skin disease (such as acne), adding ORI-001 to Sanofi’s early-stage pipeline.  What is ORI-001?  ORI-001 is a therapeutic vaccine candidate for acne vulgaris based… Read More

#News

#Biotechnology #Biotherapeutics #Clinical trials #Funding

Northwest Biotherapeutics announces $15 million financing    

Northwest Biotherapeutics, a biotechnology company developing DCVax personalised immune therapies for solid tumour cancers in the United States, has announced the closing of a $15 million financing.  The company plans to use the funding to help accelerate its activities related to its brain cancer programme.    The financing is in the form… Read More

#News

#Biopharmaceuticals #Biotechnology #Clinical trials #Covid-19 #Podcast

Clinical trials and the growing importance of technology: Podcast 

The latest sponsored DDW Sitting Down With podcast features Lisa Moneymaker and Paul O’Donohoe of Medidata and they talk to us about decentralised clinical trials. Medidata technology has helped to bring Covid-19 vaccines and treatments to market in record timelines and the company was the first to have launched a fully end-to-end Decentralised Clinical Trials (DCT) offering. Read More

#News

#Biopharmaceuticals #Biotechnology #Clinical trials #Covid-19 #Podcast #Sitting Down With

Clinical trials and the growing importance of technology

The latest sponsored DDW Sitting Down With podcast features Lisa Moneymaker and Paul O’Donohoe of Medidata and they talk to us about decentralised clinical trials. Medidata technology has helped to bring Covid-19 vaccines and treatments to market in record timelines and the company was the first to have launched a fully end-to-end Decentralised Clinical Trials (DCT) offering. Read More

#Podcasts

#Biopharma #Biotechnology #Drug innovation #Pharmaceuticals #Report #Research

Pharmaceuticals and biotech lead UK university innovation 

University technology and innovation is driving the UK's status in pharmaceuticals and biotechnology, according to GovGrant’s University Spinouts Report 2021.  The report  According to the new report, the pharmaceuticals and biotechnology sector dominates the top ten spinout companies of the last decade, ranked by valuation. Pharma and biotech companies within the top… Read More

#News #Trends & Analysis

#Assays #Biotechnology #Cell and gene therapy #Cell therapy #iPSC

Ncardia secures $60+ million for its iPSC Offerings 

Ncardia, developer of stem cell-based solutions for drug discovery and cell therapy, has secured more than $60 million in capital through a strategic partnership with Kiniciti, a US-based investment platform.  Ncardia’s capabilities include bio-reactor-based scalable manufacturing of iPSC derived cells, assay development, disease modeling, and cell-based screening. … Read More

#News

#Biotechnology #Cancer research #Funding #Infectious diseases

SpyBiotech announces VP appointment and expansion of scientific team 

SpyBiotech, a biotechnology company with a vaccine platform technology targeting infectious diseases, cancer and chronic diseases, has appointed Simon Jones as VP of Finance and Operations, and expanded its scientific team with four new hires.   Jones takes up the permanent position from Vien Phan, who held the… Read More

#News

#Biotechnology #CAR-T #Tumour #Webinar

Using ultra high-content imaging for target discovery for CAR T cell therapy 

In this free webinar, Dr. Christoph Herbel presents a newly developed workflow which combines flow cytometry–based screenings with high-parameter imaging to identify and validate new tumour markers in an unbiased approach.   The event, Kill the tumour, spare the healthy tissue. Ultra high-content imaging enables target discovery for CAR T cell therapy, was hosted by DDW and supported by Miltenyi Biotec.  It… Read More

#News #Trending News

#Biotechnology #Drug development #Inflammatory Bowel Disease #Precision medicine

The start-up changing the game for IBD 

Jenny Bailey, CEO of Ferryx tells Lu Rahman how its leading product FX856 came to life and how it’s a game-changer for inflammatory bowel disease since it can act during active inflammation.  Ferryx is an innovative bio-tech start-up. It is a University of Bristol spin-out with a focus on gut health and IBD in… Read More

#Editor's Choice #Exclusive Content #Intelligence #News #Opinion #Start-up Zone #Trends & Analysis

#AI #Biotechnology #Drug targets #Novel candidates #Precision medicine

Biotech and precision medicine tie-up addresses unmet cardiac needs 

TARA Biosystems, a biotechnology company using human biology and data for cardiac drug discovery, has collaborated with Scipher Medicine, a precision medicine company. The collaboration will address a critical unmet need for effective therapeutics in cardiac laminopathies.   Cardiac laminopathies, associated with mutations in the LMNA gene, can result in… Read More

#News #Trending News

#Biotechnology #Case study #Drug discovery #High throughput screening

Case study: Discover an innovative CRO offering unique solutions

Drug discovery contract research organizations (CROs) offer an established infrastructure and experience that offers promising paths forward for various research projects. However, partnering with a CRO also presents key challenges, and companies should consider three questions: How long until data is delivered? Will the quality of the data instill confidence… Read More

#News

#Biotechnology #Clinical trials #Covid-19 #Drug discovery #Pharmaceuticals #Pharmacology

Apeiron Biologics begins Covid-19 trial for inhaled drug candidate

Apeiron Biologics has begun a Phase I trial for inhalation of APN01, a recombinant human angiotensin-converting enzyme 2 developed to treat Covid-19 patients by neutralising SARS-CoV-2 in the lungs and mitigating lung damage caused by the infection.   The double-blind, placebo-controlled, dose-escalation study plans to enroll about 40 healthy volunteers in Austria… Read More

#News